Overcoming toxicity challenges in immune checkpoint inhibitor treatment of high-risk metastatic cancers.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: advanced cancer
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
These constraints are not unrelated, as more aggressive combinations result in higher response rates (at least in some tumors), but increase irAEs as well. Novel multidrug regimens with immune modulators may 'thread the needle' to optimize both response and toxicity concerns.
[INTRODUCTION] Immune checkpoint inhibitors (ICI) have become a cornerstone of cancer treatment and induce durable responses in many patients with advanced cancer.
APA
Nalabothu R, Johnson DB (2026). Overcoming toxicity challenges in immune checkpoint inhibitor treatment of high-risk metastatic cancers.. Expert review of anticancer therapy, 26(4), 451-461. https://doi.org/10.1080/14737140.2025.2599891
MLA
Nalabothu R, et al.. "Overcoming toxicity challenges in immune checkpoint inhibitor treatment of high-risk metastatic cancers.." Expert review of anticancer therapy, vol. 26, no. 4, 2026, pp. 451-461.
PMID
41368804 ↗
Abstract 한글 요약
[INTRODUCTION] Immune checkpoint inhibitors (ICI) have become a cornerstone of cancer treatment and induce durable responses in many patients with advanced cancer. However, they cause immune-related adverse events (irAEs) which result in symptoms related to autoimmunity, chronic sequelae, and occasionally death. Balancing toxicity and efficacy considerations remains a major challenge in ICI treatment.
[AREAS COVERED] We provide an overview of the pathophysiology, risk factors, and clinical presentation of irAEs. Next, we discuss potential approaches to manage these events. Finally, we discuss novel strategies to detect, prevent, and mitigate severe irAEs and thus optimize the benefits of ICI therapy for patients with cancer.
[EXPERT OPINION] irAEs, along with lack of response, remain the major challenge in ICI therapy. These constraints are not unrelated, as more aggressive combinations result in higher response rates (at least in some tumors), but increase irAEs as well. Novel multidrug regimens with immune modulators may 'thread the needle' to optimize both response and toxicity concerns.
[AREAS COVERED] We provide an overview of the pathophysiology, risk factors, and clinical presentation of irAEs. Next, we discuss potential approaches to manage these events. Finally, we discuss novel strategies to detect, prevent, and mitigate severe irAEs and thus optimize the benefits of ICI therapy for patients with cancer.
[EXPERT OPINION] irAEs, along with lack of response, remain the major challenge in ICI therapy. These constraints are not unrelated, as more aggressive combinations result in higher response rates (at least in some tumors), but increase irAEs as well. Novel multidrug regimens with immune modulators may 'thread the needle' to optimize both response and toxicity concerns.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.